Eli Lilly Raises Revenue Forecast Amid Strong Zepbound Sales and Competition from Viking Therapeutics
Eli Lilly (LLY) has significantly raised its sales guidance for 2026, now projecting revenue between $91 billion and $92 billion. This upward revision follows a robust third quarter where the company reported a 39% year-over-year revenue increase to $24.4 billion, fueled largely by a 49% surge in Zepbound sales, which reached $5.4 billion. While Eli Lilly dominates the weight-loss market with its dual-hormone therapy, Viking Therapeutics (VKTX) is emerging as a notable competitor. Viking's lead candidate, VK2735, has shown promising Phase 2 results with up to 14.7% mean weight loss in 13 weeks. The company is currently advancing into Phase 3 trials for its subcutaneous version and exploring oral formulations to capture the growing market for weight-loss pills.
Topics: earnings guidance GLP-1 revenue growth weight loss drugs